Mission Bio establishes early access program for single-cell measurable residual disease detection in blood cancers

ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence

The FDA Oncologic Drugs Advisory Committee voted 12:2 to recommend approval of the drug imetelstat for a myelodysplastic syndrome indication.

March 15, 2024

Vol.50 No.11

By Jacquelyn Cobb and Paul Goldberg

In Brief

University of Cincinnati opens blood cancer healing center

The University of Cincinnati Cancer Center has opened the Blood Cancer Healing Center, a facility that aims to advance research, treatment, and wellness for blood cancer patients.

February 16, 2024

Vol.50 No.07

Clinical

After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.

Yale’s Richard Edelson on what got him started in research for cutaneous T-cell lymphoma

Richard Edelson began his career at NCI, where he was training to become a cancer immunologist.

October 27, 2023

Vol.49 No.40

Drugs & Targets

FDA approves Ojjaara as first and only treatment for myelofibrosis with anemia

FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythemia), in adults with anemia.

September 22, 2023

Vol.49 No.35

In Brief

Jonathan Licht and Keith McCrae to lead new Blood specialty journals

Jonathan D. LichtKeith McCraeJonathan Licht and Keith McCrae were selected by The American Society of Hematology to serve as the inaugural editors-in-chief of the newest additions to the Blood Journals portfolio: Blood Neoplasia and Blood Vessels, Thrombosis & Hemostasis, or Blood VTH.

September 15, 2023

Vol.49 No.34

Mission Bio establishes early access program for single-cell measurable residual disease detection in blood cancers

YOU MAY BE INTERESTED IN

ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence

University of Cincinnati opens blood cancer healing center

After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

Yale’s Richard Edelson on what got him started in research for cutaneous T-cell lymphoma

FDA approves Ojjaara as first and only treatment for myelofibrosis with anemia

Jonathan Licht and Keith McCrae to lead new Blood specialty journals

Renew today!

Subscriber content

Login